Bansisons Tea Industries Ltd

Name change and strategic focus

• Name change approved to Novyra Pharmachem Limited; company expands into APIs, bulk drugs, CDMO services.
• Certificate of Incorporation for name change issued by ROC on 19 January 2026.
• New name to be updated with stock exchanges and depositories.
• Business focus includes manufacturing, processing, and global trading of APIs, bulk drugs, intermediates.

Meeting Details

• Board meeting on Friday, 14 August 2026, at the registered office of the company.

Key Agenda Items

• Unaudited financial results for the quarter ended 30 June 2026, with Limited Review Report.
• Any other business with the permission of the Chairman.

Dematerialisation processing status

• Securities received from depository participants for dematerialisation were processed.
• Mutilated dematerialisation certificates were cancelled after verification and depository names substituted in the register within 15 days.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.

Independent Directors Meeting Outcome

• Reviewed performance of non-independent directors and entire board
• Assessed chairperson's performance with input from executive and non-executive directors
• Evaluated quality, quantity, and timeliness of management-board information flow

Meeting Details ️

• Independent Directors meeting scheduled for 20th March 2026 at the company's registered office.

Key Agenda Items

• Review performance of Non-Independent Directors and the Board as a whole.
• Review the Chairperson's performance.
• Assess quantity, quality, and timeliness of information flow.